GlaxoSmithKline Recalls Rotarix; Rotavirus Vaccine Contamination Sparks Fears

GlaxoSmithKline is not having much success in light of its most recent recall of Rotarix, a rotavirus vaccine produced by the company. The recall comes on the heels of string of recalls from the company, and affects the vaccine that is designed for children six weeks to 24 weeks of age.

The most recent recall is response to a report that pig virus, PVC1, has been found in the vaccine. According to an FDA release, genetic material related to the virus was found in the vaccine, but at this time it appears that it is not harmful to humans. The recommendation, however, is based on the unknown nature of the material, as to whether it is the whole DNA structure, or just parts of the genetic material. Additionally, it has also been determined that the vaccine, according to GSKSource.com, that the virus has been present since the early stages of development, and that all vaccines issued under this name have been contaminated.

It should be noted, though, that this discovery was found through the use of a new molecular detection technique. This technique, however, sheds credibility to the statement that the virus is not harmful to humans, as the infants who have already received the vaccine have not shown any additional or abnormal reactions to the vaccine.

The primary concern appears to come from the unease of the admission from GlaxoSmithKline that they inadvertently administered contaminated vaccines to infants. The statement alone is cause for fear in panic in any new parent, and the company is likely to face a long line of concerned parents regarding the possible complications caused by the vaccine. Even though it is a common virus, found in many food sources, it is not common for parents to give pork products to six week old children.

This setback comes shortly after other recalls by the company, most notably recall of Canadian Swine Flu vaccines in November 2009. During that recall, a batch of the swine flu vaccine was thought to have caused severe and abnormal reactions in patients, and the batch, or approximately 170,000 doses, were recommended to not be used. The timing could not have been worse, as the fall of 2009 was the time which the Centers for Disease Control thought the flu would make a resurgence in the population.

Only time will tell how the recall will affect Rotavirus vaccine stockpiles, as it leaves only one other vaccine available for use. GSK is likely to spend large amounts of money to minimize damage to the company's brand, while also striving to complete research into the full effects of this contamination. Until then, there will be plenty of nervous parents hoping for the best outcome for everyone concerned.